<DOC>
	<DOCNO>NCT01740063</DOCNO>
	<brief_summary>This protocol seek enroll 372 adult otherwise healthy subject present influenza-like illness ( ILI ) . Subjects enter study base list inclusion/exclusion criterion , include positive Rapid Antigen Test ( RAT ) influenza virus ( IFV ) . Subjects randomized one three treatment group : DAS181 30 mg total dose group ( DAS181-F02 formulation ) , DAS181 60 mg total dose group ( DAS181-F04 formulation ) placebo group . The modified intent treat ( mITT ) analysis set include subject confirm influenza document qPCR TCID50 . The full analysis set use activity analysis include randomize subject baseline treatment data . Per protocol , safety analysis set describe statistical method . A subpopulation 60 participant also additional PK Immunogenicity blood sample collect . For subgroup , PK Immunogenicity sample collect study visit .</brief_summary>
	<brief_title>Phase 2B Study Safety Therapeutic Efficacy DAS181 Adult Subjects With Naturally Acquired Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Male female subject generally good health opinion investigator determine vital sign , medical history , physical exam base medical history . 2 . Subjects must able verbalize understanding consent form , provide write informed consent verbalize willingness complete study procedure . 3 . Be 18 70 year age ( inclusive ) . 4 . Subjects must weigh least 50 kg must Body Mass Index ( BMI ) great 40.00 . 5 . Febrile , oral temperature ≥100.4°F ( ≥38.0°C ) combination symptom 6 . At least one respiratory symptom : Cough Sore throat Wheezing Sneezing Shortness breath Nasal congestion Earache Pleuritic chest pain 7 . At least one constitutional symptom : Headache Myalgia ( body ache pain ) Fever feverish ( sweat/chills ) Prostration ( fatigue , tire , lack energy ) 8 . Positive rapid antigen test ( RAT ) influenza perform use FDAcleared CLIAwaived commercially available rapid antigen test supply sponsor . 9 . Blood pressure within normal limit ( systolic 90150 mmHg ; diastolic 5095 mmHg ) heart rate 45 140 beat per minute . 10 . Onset symptoms 48 hour prior diagnosis . Note : Time onset illness define either : 1. time temperature first measure elevate ( 38 C ) OR 2. time subject experienced presence least one symptom , whichever occur first 11 . Female subject must postmenopausal ( one year great without menses ) , surgically incapable childbearing , practice two effective method birth control . Acceptable method may include intrauterine device , spermicide , barrier hormonal contraception . A female subject must agree practice acceptable method birth control study period . All female subject regardless menopausal status surgical history must negative urine pregnancy test screen visit prior dose . 12 . Male subject must agree use medically accept form contraception study period . 1 . Have receive investigational drug investigational vaccine within 8 week prior study drug dosing . 2 . Have serious adverse reaction previous episode anaphylaxis related drug . 3 . Have receive blood product within 6 month study enrollment . 4 . Have concurrent cystic fibrosis emphysema . 5 . Have sickle cell disease . 6 . Known IGE mediate allergic response lactose ( lactose intolerance ) . 7 . Any history congenital acquire bleeding abnormality . 8 . Existence surgical , medical , laboratory condition , judgment clinical investigator , might interfere safety , distribution , metabolism excretion drug . 9 . Use antiviral influenza medication within 10 day prior screen ( Subjects prohibit take antiviral influenza medication course trial ) . 10 . Current clinical evidence recognize suspect uncontrolled noninfluenza infectious illness onset prior screen . 11 . Known hypersensitivity DAS181 . 12 . Women pregnant ( urine pregnancy test ) , attempt become pregnant , breastfeed . 13 . Uncontrolled seizure disorder history seizure activity within 12 month prior study participation . 14 . Any significant finding subject 's medical history physical examination , opinion investigator , would affect subject safety compliance dose schedule . 15 . Subjects history asthma chronic obstructive pulmonary disease ( COPD ) require use acute chronic medication past 3 year . 16 . Subjects acute diagnosis chronic medical condition within last 3 month . 17 . Subjects chronic medical condition initiate change dose regimen prescription medication treat chronic medical condition within last 3 month . ( Any change chronic medication 28 day enrollment period capture source documentation concomitant medication ) . 18 . Subjects current previous history follow : systemic disorder , immunological disorder , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) cirrhosis , transplant recipient , immunosuppressive illness . 19 . Subjects cancer history hematologic malignancy . Cancer define active neoplastic disease exclude noninvasive basal cell carcinoma . 20 . Subjects schedule surgery within 30 day initiation study . 21 . Subjects donate lose 500 mL blood two month prior screen . 22 . Psychiatric cognitive illness recreational drug/alcohol use , opinion principal investigator , would affect subject safety and/or compliance . 23 . Family member site staff directly involve study conduct exclude study participation . 24 . Subjects oxygen saturation ( Sa02 ) level &lt; 92 % measure pulse oximeter . 25 . Subjects modify CURB65 score 2 high .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>